Last reviewed · How we verify

NCT04376281

The Effect of Norepinephrine on Cardiac Output in Patients Undergoing Liver Transplant .

Completed NA Last updated 9 November 2021
What this trial tests

NA trial testing Noradrenaline in Liver Transplantation in 31 participants. Completed in 1 October 2021.

Timeline
15 December 2019
Primary endpoint
1 August 2021
1 October 2021

Quick facts

Lead sponsorCairo University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment31
Start date15 December 2019
Primary completion1 August 2021
Estimated completion1 October 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 18 to 65, any sex, with Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Early administration of NE in liver transplant recipient might enhance cardiac output through an increase in cardiac preload .

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Noradrenaline

Trials testing the same drug.

Other recruiting trials for Liver Transplantation

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04376281.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing